New Drug Approved for Early Alzheimer’s - The New York Times
WEBJul 2, 2024 · The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
FDA advisers endorse Eli Lilly’s early-stage Alzheimer’s drug donanemab
WEBJun 11, 2024 · On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow the progression of...
Experimental Alzheimer's drug donanemab outperforms Leqembi in ... - NPR
WEBJul 17, 2023 · In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.
FDA approves donanemab, Eli Lilly’s treatment for early ... - CNN
WEBJul 2, 2024 · The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease.
News Release - Eli Lilly and Company
WEBJul 2, 2024 · Kisunla™ (donanemab-azbt) (pronounced kih-SUHN-lah) is an amyloid-targeting treatment for people with mild cognitive impairment (MCI) as well as people with mild dementia stage of early symptomatic Alzheimer's …
News Release - Eli Lilly and Company
WEBMay 3, 2023 · Donanemab treatment slowed clinical decline by 35% compared to placebo, and resulted in 40% less decline on the ability to perform activities of daily living. Over half of all participants completed their course of treatment by 12 months
FDA approves treatment for adults with Alzheimer’s disease
WEBJul 2, 2024 · The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild...
NIA statement on donanemab results: More Alzheimer’s research …
WEBJul 17, 2023 · The results showed donanemab slowed the rates of cognitive and functional decline in participants who have early symptoms of Alzheimer’s. In particular, 47% of those who received the drug, compared to 29% who received a placebo, showed no signs of cognitive decline after one year of treatment.
Alzheimer’s drug donanemab helps most when taken at earliest
WEBJul 17, 2023 · Like many others in the newest generation of Alzheimer’s drugs, donanemab is a monoclonal antibody that targets amyloid, a sticky, neuron-damaging protein, in the brains of people with dementia.
Alzheimer’s drug donanemab: what promising trial means for
WEBMay 4, 2023 · Alzheimer’s drug donanemab: what promising trial means for treatments. Results suggest that the amyloid-targeting drug candidate slows cognitive decline in some people, but questions remain over...
- Some results have been removed